1.935

1.28% -0.025

Alx Oncology Holdings Inc (ALXO)

Overview News Price History Option Chain Financials Discussions Forecast

Alx Oncology Holdings Inc stock is traded at $1.935, with a volume of 448.94K. It is down -1.28% in the last 24 hours and down -7.86% over the past month. ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Previous Close:

$1.96

Open:

$1.93

24h Volume:

448.94K

Relative Volume:

0.33

Market Cap:

$268.26M

Revenue:

Net Income/Loss:

$-101.70M

P/E Ratio:

-1.0205

EPS:

-1.8961

Net Cash Flow:

$-84.35M

1W Performance:

-6.07%

1M Performance:

-7.86%

6M Performance:

-14.76%

1Y Performance:

+200.33%

1-Day Range:

$1.905

$2.00

1-Week Range:

$1.90

$2.09

52-Week Range:

$0.6601

$2.66

Alx Oncology Holdings Inc Stock (ALXO) Company Profile

Name

Alx Oncology Holdings Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

650-466-7125

Address

323 ALLERTON AVENUE, SOUTH SAN FRANCISCO

Employee

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

ALXO's Discussions on Twitter

Compare ALXO vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALXO Alx Oncology Holdings Inc	1.94	271.02M	0	-101.70M	-84.35M	-1.8961
VRTX Vertex Pharmaceuticals Inc	514.89	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	807.61	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	992.05	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	211.65	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	361.72	39.31B	5.76B	514.49M	1.10B	4.4813

Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-19-26	Initiated	Wells Fargo	Overweight
Mar-06-26	Resumed	UBS	Buy
Nov-13-25	Initiated	Jefferies	Buy
Mar-06-25	Upgrade	Jefferies	Hold → Buy
Dec-19-24	Downgrade	Jefferies	Buy → Hold
Mar-08-24	Downgrade	Stifel	Buy → Hold
Dec-08-23	Upgrade	Jefferies	Hold → Buy
Dec-22-21	Downgrade	Jefferies	Buy → Hold
Sep-30-21	Initiated	Stifel	Buy
May-05-21	Resumed	Credit Suisse	Outperform
Apr-26-21	Resumed	Credit Suisse	Outperform
Apr-06-21	Initiated	UBS	Buy
Feb-10-21	Initiated	H.C. Wainwright	Buy
Aug-11-20	Initiated	Cantor Fitzgerald	Overweight
Aug-11-20	Initiated	Credit Suisse	Outperform
Aug-11-20	Initiated	Jefferies	Buy
Aug-11-20	Initiated	Piper Sandler	Overweight

View All

Alx Oncology Holdings Inc Stock (ALXO) Latest News

Aug 15, 2026

ALX Oncology (ALXO) Holds Near $1.96 as Biotech Stock Consolidates Below ResistanceSingle Stock ETF - dars.gov.et

Aug 15, 2026

ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Aug 15, 2026

Aug 14, 2026

TCG Crossover group (NASDAQ: ALXO) reports 4.2% ALX Oncology stake in 13G/A - Stock Titan

Aug 14, 2026

Aug 11, 2026

Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Aug 11, 2026

H.C. Wainwright Maintains ALX Oncology(ALXO.US) With Buy Rating, Maintains Target Price $4 - Moomoo

Aug 11, 2026

Aug 10, 2026

ALX Oncology Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 10, 2026

Aug 07, 2026

ALX Oncology Holdings Inc expected to post a loss of 15 cents a shareEarnings Preview - TradingView

Aug 07, 2026

Aug 06, 2026

ALX Oncology (NASDAQ:ALXO) Issues Earnings Results - MarketBeat

Aug 06, 2026

ALX Oncology Holdings Inc 2Q 2026: Net loss $17.97M, Diluted EPS $(0.13) — 10-Q Summary - TradingView

Aug 06, 2026

ALXO: Q2 2026 net loss narrowed, expenses fell, and cash reserves support operations into 2028 - TradingView

Aug 06, 2026

Is ALX Oncology Holdings Inc (ALXO) Turning a Corner After Q2 Ea - GuruFocus

Aug 06, 2026

ALX Oncology Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 06, 2026

ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Investing News Network

Aug 06, 2026

ALX Oncology Reports Q2 2026 Net Loss of $18 Million - Quiver Quantitative

Aug 06, 2026

ALX Oncology reports Q2 2026 net loss of $18.0M, $153.4M cash; advances evorpacept and ALX2004 - TradingView

Aug 06, 2026

ALXO: Reduced net loss, robust cash position, and advancing clinical milestones drive outlook - TradingView

Aug 06, 2026

Clinical pipeline accelerates as ALX Oncology posts Q2 results and updates on ALX2004 study - Traders Union

Aug 06, 2026

Aug 05, 2026

ALXO Q2'26 Earnings: EPS estimate is (0.14) USD - TradingView

Aug 05, 2026

Aug 04, 2026

ALX Oncology (ALXO) Projected to Post Earnings on Tuesday - MarketBeat

Aug 04, 2026

Aug 02, 2026

ALX Oncology Holdings (ALXO) Holds Steady Near $1.94 as Biotech Sector Watches Key LevelsUnusual Call Volume - dars.gov.et

Aug 02, 2026

Jul 31, 2026